Market Closed -
Nasdaq
04:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
27.47
USD
|
-7.26%
|
|
-4.35%
|
+203.54%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
957.7
|
1,115
|
1,474
|
670.6
|
2,833
|
-
|
-
|
Enterprise Value (EV)
1 |
629.5
|
709.2
|
863.7
|
670.6
|
2,833
|
2,833
|
2,833
|
P/E ratio
|
-12.4
x
|
-8.34
x
|
-6.64
x
|
-3.11
x
|
-9.21
x
|
-8.7
x
|
-9.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
141
x
|
120
x
|
160
x
|
70.1
x
|
192
x
|
233
x
|
33
x
|
EV / Revenue
|
141
x
|
120
x
|
160
x
|
70.1
x
|
192
x
|
233
x
|
33
x
|
EV / EBITDA
|
-21.8
x
|
-9.49
x
|
-8.31
x
|
-2.87
x
|
-9.4
x
|
-8.04
x
|
-
|
EV / FCF
|
-25.1
x
|
-11.3
x
|
-10.6
x
|
-
|
-13.8
x
|
-10.8
x
|
-12.9
x
|
FCF Yield
|
-3.99%
|
-8.84%
|
-9.43%
|
-
|
-7.26%
|
-9.27%
|
-7.73%
|
Price to Book
|
3.13
x
|
2.58
x
|
2
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,527
|
46,897
|
66,447
|
74,101
|
95,637
|
-
|
-
|
Reference price
2 |
25.52
|
23.77
|
22.19
|
9.050
|
29.62
|
29.62
|
29.62
|
Announcement Date
|
3/15/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.319
|
6.787
|
9.326
|
9.224
|
9.56
|
14.77
|
12.14
|
85.89
|
EBITDA
1 |
-
|
-43.9
|
-117.4
|
-177.5
|
-233.5
|
-301.4
|
-352.5
|
-
|
EBIT
1 |
-
|
-44.28
|
-118.1
|
-178.9
|
-235.6
|
-309.4
|
-346.6
|
-319.4
|
Operating Margin
|
-
|
-652.38%
|
-1,265.83%
|
-1,939.65%
|
-2,464.41%
|
-2,094.03%
|
-2,855.59%
|
-371.85%
|
Earnings before Tax (EBT)
1 |
-
|
-44.36
|
-118
|
-174
|
-212.2
|
-294.8
|
-328
|
-308
|
Net income
1 |
-
|
-44.36
|
-118
|
-174
|
-212.2
|
-291.7
|
-326.4
|
-308
|
Net margin
|
-
|
-653.53%
|
-1,265.38%
|
-1,886.33%
|
-2,219.87%
|
-1,974.2%
|
-2,688.73%
|
-358.53%
|
EPS
2 |
-4.320
|
-2.050
|
-2.850
|
-3.340
|
-2.910
|
-3.215
|
-3.404
|
-2.990
|
Free Cash Flow
1 |
-
|
-38.21
|
-98.55
|
-139.1
|
-
|
-205.6
|
-262.6
|
-219
|
FCF margin
|
-
|
-562.97%
|
-1,056.76%
|
-1,507.92%
|
-
|
-1,391.57%
|
-2,163.75%
|
-255.01%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/3/20
|
3/15/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.852
|
1.795
|
2.178
|
2.482
|
2.769
|
2.233
|
2.316
|
2.818
|
2.193
|
3.543
|
3.013
|
5.156
|
3.013
|
6.796
|
6.046
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-76.55
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-38.55
|
-34.46
|
-46.3
|
-44.93
|
-53.22
|
-57.6
|
-52.63
|
-58.62
|
-66.74
|
-77.19
|
-73.7
|
-73.96
|
-79.11
|
-65.24
|
-65.97
|
Operating Margin
|
-2,081.37%
|
-1,919.78%
|
-2,125.76%
|
-1,810.19%
|
-1,922.17%
|
-2,579.31%
|
-2,272.63%
|
-2,080.38%
|
-3,043.46%
|
-2,178.58%
|
-2,446.05%
|
-1,434.49%
|
-2,625.54%
|
-960.11%
|
-1,091.19%
|
Earnings before Tax (EBT)
1 |
-38.54
|
-34.24
|
-45.69
|
-43.6
|
-50.47
|
-52.39
|
-47.02
|
-52.36
|
-60.44
|
-68.86
|
-72.57
|
-72.97
|
-78.76
|
-55.75
|
-57.88
|
Net income
1 |
-38.54
|
-34.24
|
-45.69
|
-43.6
|
-50.47
|
-52.39
|
-47.02
|
-52.36
|
-60.44
|
-68.86
|
-72.23
|
-73.68
|
-75.68
|
-55.75
|
-57.88
|
Net margin
|
-2,080.89%
|
-1,907.24%
|
-2,097.8%
|
-1,756.61%
|
-1,822.72%
|
-2,346.35%
|
-2,030.44%
|
-1,857.98%
|
-2,756.18%
|
-1,943.41%
|
-2,397.31%
|
-1,429.08%
|
-2,511.79%
|
-820.45%
|
-957.46%
|
EPS
2 |
-0.8400
|
-0.7100
|
-0.9200
|
-0.8200
|
-0.8800
|
-0.7400
|
-0.6600
|
-0.7100
|
-0.7900
|
-0.7900
|
-0.7775
|
-0.7888
|
-0.7962
|
-0.7233
|
-0.7367
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/10/22
|
8/9/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/8/23
|
2/28/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
328
|
406
|
611
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-38.2
|
-98.6
|
-139
|
-
|
-206
|
-263
|
-219
|
ROE (net income / shareholders' equity)
|
-
|
-36.8%
|
-34.3%
|
-36.3%
|
-
|
-53.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
8.150
|
9.210
|
11.10
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.09
|
3.74
|
2.82
|
4.23
|
1.22
|
0.4
|
0.42
|
Capex / Sales
|
-
|
16.09%
|
40.1%
|
30.6%
|
44.23%
|
8.22%
|
3.3%
|
0.49%
|
Announcement Date
|
4/3/20
|
3/15/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
29.62
USD Average target price
45.25
USD Spread / Average Target +52.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +203.54% | 2.83B | | -1.62% | 89.22B | | +1.32% | 40.49B | | -15.73% | 32.79B | | +64.13% | 26.23B | | -21.28% | 14.52B | | -8.50% | 13.09B | | -44.07% | 11.6B | | -13.06% | 11.5B | | +4.94% | 8.82B |
Biopharmaceuticals
|